SCHEMBL13699253

SCHEMBL13699253

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(NC(=O)c3ccc(OC4CC5CCC(C4)N5CCOC)cc3)cc2)c(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 10/20 0.43
PKM P14618 1/20 0.42
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
FGFR1 P11362 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
NAMPT P43490 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13699169 0.96 MCHR1 (0.42) MCHR1PKMRAB9ASMN1; SMN2NPC1
SCHEMBL4229209 0.95 PKM (0.43) MCHR1PKMRAB9ASMN1; SMN2NPC1
SCHEMBL13699320 0.94 PKM (0.42) MCHR1PKMRAB9ASMN1; SMN2NPC1
SCHEMBL13699167 0.93 MAPT (0.42) MCHR1PKMRAB9ASMN1; SMN2NPC1
SCHEMBL13699252 0.93 PKM (0.44) MCHR1PKMRAB9ASMN1; SMN2NPC1
SCHEMBL13699277 0.93 PKM (0.45) MCHR1PKMRAB9ASMN1; SMN2NPC1
SCHEMBL13699257 0.93 PKM (0.41) MCHR1PKMRAB9ASMN1; SMN2NPC1
SCHEMBL13699175 0.92 PKM (0.40) MCHR1PKMRAB9ASMN1; SMN2NPC1
SCHEMBL13699170 0.91 KMT2A (0.40) MCHR1PKMRAB9ASMN1; SMN2NPC1
SCHEMBL13699349 0.91 MCHR1 (0.42) MCHR1PKMRAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R MCHR1 47/4885PKM 1734/4885RAB9A 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.